首页 文献索引 SCI期刊 AI助手
条件筛选
相关性 最新发表 最早发表
全文 标题 期刊 作者
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
模糊 精准
{{tag.shortname||tag.name}}:{{getFilterLabel(field)}} Clear All
Han Zhou,Tonglian Zhou,Wenli Yu et al. Han Zhou et al.
Proteolysis-targeting chimeras (PROTACs) enable the selective and sub-stoichiometric elimination of pathological proteins, yet only two E3 ligases are routinely used for this purpose. Here, we expand the repertoire of PROTAC-compatible E3 l...
Dian Xiao,Jingwen Dong,Fei Xie et al. Dian Xiao et al.
Lysosome-targeting chimeras (LYTACs) represent a revolutionary targeted protein degradation technology. However, the advancement of LYTACs faces substantial challenges due to the limited diversity of lysosome-trafficking receptors.
Xiaoqiang He,Shihan Zeng,Yalei Wen et al. Xiaoqiang He et al.
Targeted protein degradation (TPD) has emerged as a promising therapeutic strategy for treating various diseases. However, current small molecule degraders predominantly rely on a limited set of E3 ubiquitin ligases, such as CRBN and VHL, w...
Zhangping Xiao,Efthymios S Gavriil,Fangyuan Cao et al. Zhangping Xiao et al.
Targeted protein degradation (TPD) is a rapidly emerging and potentially transformative therapeutic modality. However, the large majority of >600 known ubiquitin ligases have yet to be exploited as TPD effectors by proteolysis-targeting chi...
Yunan Zheng,Anamika Singh,Zeqi Niu et al. Yunan Zheng et al.
A major challenge in evaluating the suitability of ∼700 known and putative E3 ligases for target protein degradation (TPD) is the lack of ligase-specific binders. Here, we use genetic code expansion (GCE) to express in living cells an E3 l...
Jiwei Chen,Shuo Wang,Tong Li et al. Jiwei Chen et al.
Introduction: Despite the booming targeted protein degradation technologies, degrading cell membrane proteins remains an enormous challenge. In particular, only a limited approach is appropriate for the degradation of the G protein-coupled receptor (GPCR) superfamily.
Shujing Xu,Ya Wang,Dazhou Shi et al. Shujing Xu et al.
Novel anti-HBV agents are urgently needed to overcome drug resistance challenges, with targeted protein degradation (TPD) emerging as a hopeful strategy.
Yuxin Fang,Yaojin Zhu,Wei Wang et al. Yuxin Fang et al.
Membrane protein degradation is a cutting-edge field in targeted protein degradation (TPD). Herein, we developed glypican-3 (GPC3)-mediated lysosome-targeting chimeras (GLTACs) as a novel strategy for the targeted degradation of tumor-specific membrane proteins.
Rongjun Zhang,Changjie Yang,Xiaobo Gao et al. Rongjun Zhang et al.
In this study, we develop a multifunctional phototriggered LYTAC platform, named PT-LYTAC, to enhance targeted protein degradation using a photoactive bispecific aptamer chimera (PBAC)....By the combination of targeted protein degradation and spatiotemporally controllable regulation of intracellular oxidative stress, the function of tumor cells can be significantly inhibited.
耗时 0.14756 秒,为您在 48229835 条记录里面共找到 706 篇文章 [XML]